Claims for Patent: 7,067,648
✉ Email this page to a colleague
Summary for Patent: 7,067,648
Title: | Regulatory sequences of the mouse villin gene--use in transgenesis |
Abstract: | The invention relates to regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of the intestine and uro-genital tracts. The invention also relates to recombinant constructs comprising said regulatory sequences, for the control of the targeted expression of determined nucleic acid sequences so-called (heterologous sequences or also transgenes), in cells or tissues originating from the intestinal mucosa. A further object of the invention is to provide cells, tissues or organisms including animals, expressing said determined nucleic acid sequences in a targeted manner. |
Inventor(s): | Pinto; Daniel (Bagnolet, FR), Robine; Sylvie (Vanves, FR), Jaisser; Frederic (Malakoff, FR), Louvard; Daniel (Sceaux, FR) |
Assignee: | Institut Curie (FR) Centre National de la Recherche and Scientifique (FR) |
Application Number: | 09/877,935 |
Patent Claims: | 1. An isolated nucleotide sequence obtained from the 5' sequence of a murine villin gene, having: i) a size of 9 kb on an agarose gel and comprising SEQ ID NO:1, or ii) a
fragment within i), wherein said nucleotide sequence comprises nucleotide elements having a cis-regulatory activity that promotes transcription and tissue-specific expression of the murine villin gene in cells of the intestine.
2. The isolated nucleotide sequence according to claim 1, which is the sequence identified as Seq ID NO:1. 3. The isolated nucleotide sequence according to claim 1, which comprises the nucleotide fragment extending from the HS I to the HS IV Dnase I-hypersensitive sites. 4. The isolated nucleotide sequence according to claim 1, comprising a nucleotide fragment extending from the HS IV Dnase-I hypersensitive site to the translation initiation site of the murine villin gene. 5. The isolated nucleotide sequence according to claim 1, which comprises a nucleotide fragment extending from the nucleotide at position -100 upstream from the transcription initiation site, to the translation initiation site. 6. The isolated nucleotide sequence according to claim 1, which comprises a nucleotide fragment extending from the nucleotide at position -480 from the transcription initiation sequence, to the translation initiation site. 7. The isolated nucleotide sequence according to claim 1, which is the sequence extending from the translation initiation site of said murine villin gene upstream to a sequence that is 3.5 kb upstream from the transcription initiation site of said murine villin gene, provided the intron 1 region, located between said sites, is deleted or deleted in part. 8. The isolated nucleotide sequence according to claim 1, which is mutated by deletion of one or several nucleotides, within the nucleotide fragment of 5.5 kb corresponding to the intron 1 region extending from position 47 starting from the transcription initiation site, provided that said mutation does not affect the presence of the HS II Dnase I-hypersensitive site. 9. The isolated nucleotide sequence according to claim 1, which comprises nucleotide regions having a regulatory activity affecting the level of expression of the murine villin gene. 10. The isolated nucleotide sequence according to claim 1, which is obtained from the nucleotide sequence of the murine villin gene having a size of 9 kb on an agarose gel and extending 3.5 kb upstream from the transcription initiation site and 5.5 kb downstream from said site, or a fragment thereof, said nucleotide sequence or fragment thereof having a regulatory activity on the level of expression of the murine villin gene in transgenic mice. 11. An isolated nucleotide sequence obtained from the 5' sequence of a murrine villin gene having i) a size of 9 kb on an agarose gel and is the sequence identified as SEQ ID NO:1; or ii) a fragment of i), wherein said fragment is selected from the group consisting of (a) a nucleotide fragment extending from the translation initiation site of said murine villin gene upstream to a sequence that is 3.5 kb upstream from the transcription initiation site of said murine villin gene, provided the intron 1 region located between said sites is deleted; (b) a nucleotide fragment extending from the HS I to the HS IV Dnase-I hypersensitive sites; (c) a nucleotide fragment extending from the HS IV Dnase-I hypersensitive site downstream to the translation initiation site of the murine villin gene; (d) a nucleotide fragment extending from the nucleotide at position -100 upstream from the transcription initiation site to the translation initiation site; and (e) a nucleotide fragment extending from the nucleotide at position -480 from the transcription initiation sequence to the translation initiation site; wherein said nucleotide sequence comprises nucleotide elements having cis-regulatory activity that promote the transcription of the murine villin gene. 12. An isolated nucleotide sequence obtained from the 5' sequence of a murine villin gene which is the sequence extending 3.5 kb upstream and 5.5 kb downstream from the transcription initiation site of the murine villin gene. 13. An isolated nucleotide sequence obtained from the 5' sequence of a murine villin having i) a size of 9 kb on an agarose gel and is the sequence identified as SEQ ID NO:1; or ii) a fragment of i), wherein said fragment is selected from the group of: (a) a nucleotide fragment extending from the translation initiation site of said murine villin gene upstream to a sequence that is 3.5 kb upstream from the transcription initiation site of said murine villin gene, provided the intron 1 region is located between said sites is deleted; (b) a nucleotide fragment extending from the HS I to the HS IV Dnase-I hypersensitive sites; (c) a nucleotide fragment extending from the HS IV Dnase-I hypersensitive site downstream to the translation initiation site of the murine villin gene; (d) a nucleotide fragment extending from the nucleotide at position -100 upstream from the transcription initiation site, to the translation initiation site; and (e) a nucleotide fragment extending from the nucleotide at position -480 from the transcription initiation sequence, to the translation initiation site; wherein said isolated nucleotide sequence comprises nucleotide elements having a cis-regulatory activity that promotes the transcription of the murine villin gene and comprises nucleotide regions having a regulatory activity affecting the level of expression of the murine villin gene. 14. An isolated nucleotide sequence obtained from the 5' sequence of a murine villin gene, having: i) a size of 9 kb on an agarose gel and is the sequence identified as SEQ ID NO:1; or ii) a fragment within i), wherein said isolated nucleotide sequence comprises nucleotide elements having a cis-regulatory activity that promotes the transcription and tissue-specific expression of the murine villin gene in intestine epithelial cells and kidney proximal tubules. 15. The isolated nucleotide sequence according to claim 14, which comprises nucleotide regions having a regulatory activity affecting the level of expression of the murine villin gene. 16. An isolated nucleotide sequence obtained from the 5' sequence of a murine villin gene having; i) a nucleotide fragment extending from an HS IV Dnase I-hypersensitive site downstream to the translation initiation site of the murine villin gene and extending 3.5 kb upstream of the transcription initiation site of SEQ ID NO:1; or ii) a fragment within i), wherein said isolated nucleotide sequence comprises nucleotide elements having a cis-regulatory activity that promotes the transcription and tissue-specific expression of the murine villin gene in intestine epithelial cells and kidney proximal tubules. |
Details for Patent 7,067,648
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2018-12-09 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2018-12-09 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2018-12-09 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.